NASDAQ · PALI
Palisade Bio, Inc.
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
Loading market information…
NASDAQ · HOTH · USD
Stock price, earnings
Quote as of Aug 5, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Hoth Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hoth Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 9, 2024 |
| -$0.24+38.46% vs estimate |
| $0.00 |
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
$3.31-$0.19 (-5.43%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.35% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$0.68+$0.00 (+0.22%)
Dare Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.97% below the high.
$3.77+$0.47 (+14.24%)
Lexaria Bioscience Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.55% below the high.
$0.93-$0.04 (-3.99%)
FibroBiologics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 90.33% below the high.
$1.89+$0.04 (+2.16%)
Processa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.56% below the high.
$1.42-$0.09 (-5.67%)
Pulmatrix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.64% below the high.
